HER2 Biology: Enhertu Expands Cancer Reach

Key Takeaways

• NCI describes fam-trastuzumab deruxtecan-nxki as a HER2-directed antibody–drug conjugate linking trastuzumab to a topoisomerase I inhibitor payload.
• FDA approved Enhertu with pertuzumab on December 15, 2025 for first-line unresectable or metastatic HER2-positive breast cancer.
• FDA approved Enhertu on January 27, 2025 for unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy progression.
• On May 15, 2026, FDA approved separate neoadjuvant and adjuvant Enhertu indications in early-stage HER2-positive breast cancer.

What is HER2 biologically, and why do ADCs change the map?

HER2 (ERBB2) is a receptor tyrosine kinase that can drive tumor growth when overexpressed or amplified. Classic HER2-positive breast cancer relied on IHC 3+ or ISH amplification. Antibody–drug conjugates such as fam-trastuzumab deruxtecan-nxki bind HER2 and deliver a cytotoxic payload that can also affect neighboring cells, which helps explain activity in lower HER2 expression bands.

NCI drug information: NCI — fam-trastuzumab deruxtecan-nxki.

How far has FDA pushed HER2-low and ultralow breast cancer labeling?

On January 27, 2025, FDA approved Enhertu for unresectable or metastatic HR-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer that progressed on one or more endocrine therapies in the metastatic setting, with companion diagnostic updates for ultralow detection.

Source: FDA — HER2-low/ultralow breast cancer approval.

What changed in first-line metastatic HER2-positive disease in late 2025?

On December 15, 2025, FDA approved fam-trastuzumab deruxtecan-nxki with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, alongside companion diagnostic clearances for PATHWAY IHC and Dual ISH probes.

Source: FDA — Enhertu + pertuzumab first-line approval.

How is early-stage HER2-positive disease shifting in 2026?

On May 15, 2026, FDA approved two separate early-stage indications: neoadjuvant T-DXd followed by THP for Stage II or III HER2-positive breast cancer, and adjuvant T-DXd for residual invasive disease after neoadjuvant trastuzumab-based therapy. Companion diagnostics were again specified for IHC3+ or ISH+ selection.

Source: FDA — early-stage HER2-positive indications.

What should APAC medical affairs prioritize on testing and sequencing?

Testing algorithms must capture IHC 0 membrane staining, IHC 1+/2+, and ISH results—not only the historic positive/negative split. Sequencing debates now include whether ADC-containing first-line regimens displace older taxane–trastuzumab–pertuzumab standards in labeled populations.

• Update pathology SOWs for ultralow reporting language
• Separate metastatic versus early-stage objection handlers
• Track ILD/pneumonitis monitoring requirements in local labels

Daiichi Sankyo corporate disclosures can supplement but FDA pages remain the citation gate: Daiichi Sankyo.

What remains unproven?

HER2 biology explains target engagement; it does not by itself prove superiority of every ADC versus every TKIs or bispecific across all solid tumors. Stick to labeled populations and FDA-stated companion diagnostics when making comparative claims.

Competitive intelligence and medical reviewers should keep a dated binder of the FDA, CMS, CDC, ClinicalTrials.gov, and wire URLs used above, and should delete any claim that cannot be re-opened from those primaries within one click.

For APAC launch excellence teams, the practical HER2 workstream is diagnostic capacity: pathology networks must report IHC membrane staining at 0, 1+, and 2+, plus ISH when indicated, so that ultralow and low populations are not invisible in charts that still use a binary HER2-positive flag.

Medical information responses should separate the December 15, 2025 first-line metastatic combination approval, the January 27, 2025 endocrine-resistant HER2-low/ultralow approval, and the May 15, 2026 early-stage neoadjuvant and adjuvant decisions, because sequencing questions differ in each setting.

Safety governance remains non-negotiable: interstitial lung disease and pneumonitis monitoring language from the U.S. label must be localized carefully, and cross-trial marketing that implies class-wide ADC interchangeability without head-to-head data should be rejected in review.

Related NovaPharma coverage

• Imfinzi Imjudo liver cancer
• Merck Phase 3 pipeline
• Orphan drugs 2026

Frequently Asked Questions

Primary Sources

1. NCI — fam-trastuzumab deruxtecan-nxki
2. FDA — HER2-low/ultralow approval
3. FDA — Enhertu + pertuzumab first-line
4. FDA — early-stage HER2 indications